Bristol-Myers Squibb: Analysis Of Earnings Beat, Missed Revenues
- Bristol-Myers Squibb Company (NYSE:BMY) earnings beat estimates, up 4.19% on a year-ago basis and up almost 117% from last quarter.
- However, overall revenues missed expectations with the virology unit and their schizophrenia drug reporting below par numbers.
- Sales of Eliquis, their DVT drug though, have grown on the back on additional approvals. The oncology division has performed well too.
- Earnings growth due to the contribution of unusual items.